|Bid||9.43 x 1800|
|Ask||9.49 x 800|
|Day's Range||8.85 - 9.31|
|52 Week Range||2.54 - 35.20|
|Beta (5Y Monthly)||0.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.33|
EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December. Conference: B. Riley Fall Best Ideas in Oncology Panel Series – Overcoming Checkpoint Resistance in Solid TumorsDate and Time: Thursday, October 28, 2021 at 1
Every investor in Gritstone bio, Inc. ( NASDAQ:GRTS ) should be aware of the most powerful shareholder groups. Insiders...
Gritstone Bio (NASDAQ: GRTS) is far from being the first to the coronavirus vaccine finish line. The biotech company's vaccine candidate just began phase 1 trials this year. Gritstone's clinical trials are in the earliest stage.